ArticleScientific reports2025

A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8

Kirit Singh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.